الصفحة الرئيسية>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA/RNA Synthesis>>TH287

TH287

رقم الكتالوجGC17601

TH287 هو مثبط قوي وانتقائي لـ MTH1 ، مع IC بمقدار 0.8 نانومترTH287 انتقائي للغاية تجاه MTH1 ، مع عدم وجود تثبيط ذي صلة لـ MTH2 و NUDT5 و NUDT12 و NUDT14 و NUDT16 و dCTPase و dUTPase و ITPA عند 100 ميكرومتريمكن أن يعمل TH287 كعامل علاج كيميائي لأبحاث السرطان

Products are for research use only. Not for human use. We do not sell to patients.

TH287 التركيب الكيميائي

Cas No.: 1609960-30-6

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
46٫00
متوفر
5mg
49٫00
متوفر
10mg
68٫00
متوفر
100mg
328٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TH287 is a potent MTH1 inhibitor with IC50 of 0.8±0.1 nM. [1]

MTH1 (human MutT homolog 1) is an antimutagenic purine nucleoside triphosphatase that sanitize oxidized nucleotide pools. It’s a new cancer therapeutic target as it protects the cancer cell from DNA damages such as oxidative stress-induced cell dysfunction or death.

In U2OS and other cancer cell lines, TH287 treatment selectively and effectively kill cancer cells with less toxic to some primary or immortalized cells. U2OS cells treated with TH287 shows increase of 8-oxodG in DNA. The MTH1 inhibitor TH287 induces DNA damage and activates an ATM-p53-mediated death response and DNA repair in U2OS cells. [1]

Reference:
1.  Gad H, Koolmeister T, Jemth AS et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 2014 Apr 10;508(7495):215-21.

مراجعات

Review for TH287

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TH287

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.